Inhibition of TNF-α synthesis assay

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC cells. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA.

Cell lines

Human CD34+ erythroid progenitor cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

1 μM; 2, 6, 9, and 12 days

Applications

Pomalidomide at 1 μM increased HbF production in human erythroid cells. After 6 days, Pomalidomide at 1 μM induced γ-globin mRNA levels upregulation 2-fold while decreased β-globin levels 2-fold.

Animal models

Murine central nervous system (CNS) lymphoma models

Dosage form

3 mg/kg, 10 mg/kg, or 30 mg/kg by oral gavage daily for 28 days

Applications

Pomalidomide (3, 10, and 30 mg/kg) showed significant therapeutic activity with significant reduction in tumor growth rate and prolongation of survival in two CNS lymphoma models.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). As a derivative of thalidomide, pomalidomide has a similar chemical structure as thalidomide except for the addition of two oxo groups in the phthaloyl ring and an amino group at the fourth position. Generally, as an immunomodulatory molecule, pomalidomide demonstrates antitumor activity through a mechanism of blocking the tumor microenvironment by modulation of tumor-supporting cytokines (TNF-α, IL-6, IL-8 and VEGF), directly down-regulating key functions of tumor cells, and engaging support from non-immune host cells.

Reference

[1].AA Chanan-Khan, A Swaika, A Paulus, SK Kumar, JR Mikhael, SV Rajkumar, A Dispenzieri, and MQ Lacy. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal (2013) 3, el43
[2].Evangelos Terpos, Nikolaos Kanellias, Dimitrios Christoulas, Efstathios Kastritis, and Meletios A Dimopoulos. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther 2013; 6: 531-538